Research Update

Melatonin vs Memantine for ECT-Related Cognitive Impairment

Topics: Cognitive impairment | ECT | Melatonin | Memantine

Review of: Sarraf N et al, J Clin Neurosci 2020;74:146–150 Many patients hesitate to accept ECT because of the treatment’s adverse effects on cognitive function. Memantine (Namenda)—an NMDA receptor antagonist approved for the treatment of Alzheimer’s disease—has been shown to be more effective than placebo in preventing cognitive impairmen

Read More